{
    "info": {
        "nct_id": "NCT04158245",
        "official_title": "Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients With Metastatic Castration Resistant Prostate Cancer Treated With With Life Prolonging Therapies: A Pilot Study",
        "inclusion_criteria": "1. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2;\n2. Age ≥ 18 years;\n3. Histologically confirmed adenocarcinoma of the prostate;\n4. Ongoing use of luteinizing hormone-releasing hormone (LHRH) required in the absence of surgical castration and castrate concentration of testosterone (< 50 ng/dL);\n5. Detectable PSA of at least 2 ng/dL;\n6. Metastatic disease documented by CT or bone scan within 42 days of cycle 1 day 1;\n7. Life expectancy of ≥ 6 months;\n8. Must have disease progression despite a castrate concentration of testosterone of < 50 ng/dL based on:\n\n   A. PSA progression defined as increase in PSA of at least 2 ng/dL and 25% from nadir values of prior therapy, determined by 2 separate measurement taken at least 1 week apart;\n\n   And/or\n\n   B. Radiographic disease progression based on response evaluation criteria in solid tumors (RECIST) 1.1 for soft tissue disease and/or prostate cancer working group 3 (PCWG3) for bone only disease;\n9. No prior life-prolonging therapies for mCRPC are allowed, except Sipuleucel-T;\n10. The use of docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is allowed;\n11. Low dose prednisone (10 mg or less) or equivalent is allowed;\n12. Acceptable liver function (within 28 days from enrollment) defined as:\n\n    A. Bilirubin < 2.5 times upper limit of normal (ULN), except for patients with known Gilbert disease (in such cases bilirubin < 5 times ULN);\n\n    B. AST (SGOT) and ALT (SGPT) < 3 times ULN\n13. Acceptable renal function (within 28 days from enrollment):\n\n    A. Serum creatinine ≤ 2.0 x ULN or creatinine clearance ≥ 30 mL/min\n14. Acceptable hematologic status (within 28 days from enrollment):\n\n    A. Absolute neutrophil count (ANC) ≥ 1000 cell/mm3 (100 x 109/L)\n\n    B. Platelet count ≥ 100,000 platelet/mm3 (100 x 109/L)\n\n    C. Hemoglobin ≥ 9 g/dL\n15. At least 2 weeks since prior radiation before starting study treatment (cycle 1 day 1);\n16. Able to understand and willing to sign a written informed consent document;\n17. Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetate.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 18 Years",
        "exclusion_criteria": "1. Pathological findings consistent with small cell carcinoma of the prostate;\n2. Prior treatment with docetaxel for metastatic castration-resistant prostate cancer (CRPC);\n3. Patient with normal 18F-flucicolovine PET/CT scans at baseline;\n4. Know allergies, hypersensitivity, or intolerance to abiraterone, prednisone, 18F-fluciclovine or their excipients;\n5. Any chronic medical condition requiring ≥ 10 mg daily of systemic prednisone (or equivalent);\n6. Major surgery (e.g., required general anesthesia) within 2 weeks before screening;\n7. Uncontrolled active infection (including hepatitis B or C or AIDS). Patients with hepatitis B/C who have disease under control and no significant liver function impairment, and undetectable viral load will be allowed to participate. Similarly, patients with known HIV and ≥ 400 CD4 + T cells are allowed to participate;\n8. Evidence of other metastatic malignancies within the last year;\n9. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "5. Detectable PSA of at least 2 ng/dL;",
            "criterions": [
                {
                    "exact_snippets": "Detectable PSA of at least 2 ng/dL",
                    "criterion": "PSA level",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Age ≥ 18 years;",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "C. Hemoglobin ≥ 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2;",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance status 0-2",
                    "criterion": "ECOG Performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histologically confirmed adenocarcinoma of the prostate;",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Ongoing use of luteinizing hormone-releasing hormone (LHRH) required in the absence of surgical castration and castrate concentration of testosterone (< 50 ng/dL);",
            "criterions": [
                {
                    "exact_snippets": "Ongoing use of luteinizing hormone-releasing hormone (LHRH) required",
                    "criterion": "luteinizing hormone-releasing hormone (LHRH) use",
                    "requirements": [
                        {
                            "requirement_type": "ongoing use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of surgical castration",
                    "criterion": "surgical castration",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "castrate concentration of testosterone (< 50 ng/dL)",
                    "criterion": "testosterone concentration",
                    "requirements": [
                        {
                            "requirement_type": "concentration",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Metastatic disease documented by CT or bone scan within 42 days of cycle 1 day 1;",
            "criterions": [
                {
                    "exact_snippets": "Metastatic disease documented by CT or bone scan",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation_method",
                            "expected_value": [
                                "CT",
                                "bone scan"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 42 days of cycle 1 day 1",
                    "criterion": "metastatic disease documentation timing",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 42,
                                "unit": "days before cycle 1 day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Life expectancy of ≥ 6 months;",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Must have disease progression despite a castrate concentration of testosterone of < 50 ng/dL based on:",
            "criterions": [
                {
                    "exact_snippets": "disease progression",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "castrate concentration of testosterone of < 50 ng/dL",
                    "criterion": "testosterone concentration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "A. PSA progression defined as increase in PSA of at least 2 ng/dL and 25% from nadir values of prior therapy, determined by 2 separate measurement taken at least 1 week apart;",
            "criterions": [
                {
                    "exact_snippets": "PSA progression defined as increase in PSA of at least 2 ng/dL and 25% from nadir values of prior therapy",
                    "criterion": "PSA progression",
                    "requirements": [
                        {
                            "requirement_type": "increase from nadir",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "ng/dL"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 25,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by 2 separate measurement taken at least 1 week apart",
                    "criterion": "PSA progression measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "number of measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "measurements"
                            }
                        },
                        {
                            "requirement_type": "minimum interval between measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "B. Radiographic disease progression based on response evaluation criteria in solid tumors (RECIST) 1.1 for soft tissue disease and/or prostate cancer working group 3 (PCWG3) for bone only disease;",
            "criterions": [
                {
                    "exact_snippets": "Radiographic disease progression based on response evaluation criteria in solid tumors (RECIST) 1.1 for soft tissue disease",
                    "criterion": "radiographic disease progression (soft tissue disease)",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiographic disease progression ... prostate cancer working group 3 (PCWG3) for bone only disease",
                    "criterion": "radiographic disease progression (bone only disease)",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "PCWG3"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. No prior life-prolonging therapies for mCRPC are allowed, except Sipuleucel-T;",
            "criterions": [
                {
                    "exact_snippets": "No prior life-prolonging therapies for mCRPC are allowed, except Sipuleucel-T",
                    "criterion": "prior life-prolonging therapies for mCRPC",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "Sipuleucel-T"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Low dose prednisone (10 mg or less) or equivalent is allowed;",
            "criterions": [
                {
                    "exact_snippets": "Low dose prednisone (10 mg or less) or equivalent is allowed",
                    "criterion": "prednisone (or equivalent) dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Acceptable liver function (within 28 days from enrollment) defined as:",
            "criterions": [
                {
                    "exact_snippets": "Acceptable liver function (within 28 days from enrollment)",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days from enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "A. Bilirubin < 2.5 times upper limit of normal (ULN), except for patients with known Gilbert disease (in such cases bilirubin < 5 times ULN);",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin < 2.5 times upper limit of normal (ULN)",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for patients with known Gilbert disease (in such cases bilirubin < 5 times ULN)",
                    "criterion": "bilirubin in patients with known Gilbert disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "B. AST (SGOT) and ALT (SGPT) < 3 times ULN",
            "criterions": [
                {
                    "exact_snippets": "AST (SGOT) ... < 3 times ULN",
                    "criterion": "AST (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT (SGPT) ... < 3 times ULN",
                    "criterion": "ALT (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "times ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Acceptable renal function (within 28 days from enrollment):",
            "criterions": [
                {
                    "exact_snippets": "Acceptable renal function (within 28 days from enrollment)",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days from enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Acceptable hematologic status (within 28 days from enrollment):",
            "criterions": [
                {
                    "exact_snippets": "Acceptable hematologic status (within 28 days from enrollment)",
                    "criterion": "hematologic status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days from enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "A. Serum creatinine ≤ 2.0 x ULN or creatinine clearance ≥ 30 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 2.0 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance ≥ 30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. At least 2 weeks since prior radiation before starting study treatment (cycle 1 day 1);",
            "criterions": [
                {
                    "exact_snippets": "At least 2 weeks since prior radiation before starting study treatment (cycle 1 day 1)",
                    "criterion": "time since prior radiation",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Able to understand and willing to sign a written informed consent document;",
            "criterions": [
                {
                    "exact_snippets": "Able to understand",
                    "criterion": "understanding ability",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "document type",
                            "expected_value": "written informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetate.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetate.",
                    "criterion": "use of birth control with adequate barrier protection",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week after last dose of abiraterone acetate"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. The use of docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is allowed;",
            "criterions": [
                {
                    "exact_snippets": "The use of docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is allowed",
                    "criterion": "prior docetaxel use in mHSPC setting",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "8. Evidence of other metastatic malignancies within the last year;",
            "criterions": [
                {
                    "exact_snippets": "Evidence of other metastatic malignancies within the last year",
                    "criterion": "other metastatic malignancies",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Major surgery (e.g., required general anesthesia) within 2 weeks before screening;",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... within 2 weeks before screening",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "event occurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patient with normal 18F-flucicolovine PET/CT scans at baseline;",
            "criterions": [
                {
                    "exact_snippets": "normal 18F-flucicolovine PET/CT scans at baseline",
                    "criterion": "18F-flucicolovine PET/CT scan at baseline",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Uncontrolled active infection (including hepatitis B or C or AIDS). Patients with hepatitis B/C who have disease under control and no significant liver function impairment, and undetectable viral load will be allowed to participate. Similarly, patients with known HIV and ≥ 400 CD4 + T cells are allowed to participate;",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled active infection (including hepatitis B or C or AIDS)",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B/C who have disease under control and no significant liver function impairment, and undetectable viral load will be allowed to participate",
                    "criterion": "hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        },
                        {
                            "requirement_type": "liver function impairment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "viral load",
                            "expected_value": "undetectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known HIV and ≥ 400 CD4 + T cells are allowed to participate",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "CD4+ T cell count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 400,
                                "unit": "cells"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior treatment with docetaxel for metastatic castration-resistant prostate cancer (CRPC);",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with docetaxel for metastatic castration-resistant prostate cancer (CRPC)",
                    "criterion": "prior treatment with docetaxel",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "metastatic castration-resistant prostate cancer (CRPC)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.",
            "criterions": [
                {
                    "exact_snippets": "serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent",
                    "criterion": "pre-existing medical, psychiatric, or other condition (including laboratory abnormalities)",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        },
                        {
                            "requirement_type": "potential to interfere with patient safety or provision of informed consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathological findings consistent with small cell carcinoma of the prostate;",
            "criterions": [
                {
                    "exact_snippets": "Pathological findings consistent with small cell carcinoma of the prostate",
                    "criterion": "pathological findings",
                    "requirements": [
                        {
                            "requirement_type": "consistency with diagnosis",
                            "expected_value": "small cell carcinoma of the prostate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Any chronic medical condition requiring ≥ 10 mg daily of systemic prednisone (or equivalent);",
            "criterions": [
                {
                    "exact_snippets": "Any chronic medical condition requiring ≥ 10 mg daily of systemic prednisone (or equivalent)",
                    "criterion": "chronic medical condition",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requires ≥ 10 mg daily of systemic prednisone (or equivalent)"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring ≥ 10 mg daily of systemic prednisone (or equivalent)",
                    "criterion": "systemic prednisone (or equivalent) dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg daily"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "And/or",
            "criterions": []
        },
        {
            "line": "A. Absolute neutrophil count (ANC) ≥ 1000 cell/mm3 (100 x 109/L)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000 cell/mm3 (100 x 10^9/L)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cell/mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "B. Platelet count ≥ 100,000 platelet/mm3 (100 x 109/L)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100,000 platelet/mm3 (100 x 10^9/L)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "platelet/mm3"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "4. Know allergies, hypersensitivity, or intolerance to abiraterone, prednisone, 18F-fluciclovine or their excipients;",
            "criterions": [
                {
                    "exact_snippets": "allergies, hypersensitivity, or intolerance to abiraterone",
                    "criterion": "allergy, hypersensitivity, or intolerance to abiraterone",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergies, hypersensitivity, or intolerance to prednisone",
                    "criterion": "allergy, hypersensitivity, or intolerance to prednisone",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergies, hypersensitivity, or intolerance to 18F-fluciclovine",
                    "criterion": "allergy, hypersensitivity, or intolerance to 18F-fluciclovine",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergies, hypersensitivity, or intolerance to ... their excipients",
                    "criterion": "allergy, hypersensitivity, or intolerance to excipients of abiraterone, prednisone, or 18F-fluciclovine",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}